# US 2023/0272079 A1 · Monoclonal Antibodies to Programmed Death 1 (PD-1)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272079 A1
- Document ID: US20230272079A1
- Status: Published application
- Kind: A1
- Application number: 18/167,012
- Filed: 2023-02-09
- Published: 2023-08-31
- Earliest claimed: 2005-05-09
- Assignees: E.R. Squibb & Sons, Inc.; Ono Pharmaceutical Co., Ltd.
- Applicants: E.R. Squibb & Sons, L.L.C.; Ono Pharmaceutical Co., LTD.
- Inventors: Alan J. KORMAN; Mohan SRINIVASAN; Changyu WANG; Mark J. SELBY; Bingliang CHEN; Josephine M. CARDARELLI; Haichun HUANG
- Web page: https://patentgrep.com/patent/US20230272079A1

## CPC

- C07K 16/2818: {against CD28 or CD152}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 51/10: Antibodies or immunoglobulins; Fragments thereof {, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody}
- A61P 7/06: Antianaemics
- C07K 16/18: against material from animals or humans
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/74: Inducing cell proliferation
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.

## Claims

### Claim at position 1

1-21. (canceled)

### Claim 22

An isolated monoclonal antibody, or antigen-binding portion thereof, comprising a heavy chain variable region that comprises CDR1, CDR2, and CDR3 sequences; and a light chain variable region that comprises CDR1, CDR2, and CDR3 sequences, wherein:
a) the heavy chain variable region CDR3 sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 29, 30, 31, 32, 33, 34 and 35, and conservative modifications thereof,
b) the light chain variable region CDR3 sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 50, 51, 52, 53, 54, 55 and 56, and conservative modifications thereof, and
c) the antibody or the antigen-binding portion thereof specifically binds to PD-1.

### Claim 23 (depends on 22)

The antibody of claim 22, wherein the heavy chain variable region CDR2 sequence comprises an amino acid sequence selected from the group consisting of amino acid sequences of SEQ ID NOs: 22, 23, 24, 25, 26, 27 and 28, and conservative modifications thereof; and the light chain variable region CDR2 sequence comprises an amino acid sequence selected from the group consisting of amino acid sequences of SEQ ID NOs: 43, 44, 45, 46, 47, 48 and 49, and conservative modifications thereof.

### Claim 24 (depends on 23)

The antibody of claim 23, wherein the heavy chain variable region CDR1 sequence comprises an amino acid sequence selected from the group consisting of amino acid sequences of SEQ ID NOs: 15, 16, 17, 18, 19, 20 and 21, and conservative modifications thereof; and the light chain variable region CDR1 sequence comprises an amino acid sequence selected from the group consisting of amino acid sequences of SEQ ID NOs: 36, 37, 38, 39, 40, 41 and 42, and conservative modifications thereof.

### Claim at position 5

25-51. (canceled)

### Claim 52 (depends on 22)

An isolated nucleic acid molecule encoding the antibody, or antigen-binding portion thereof, of claim 22.

### Claim 53 (depends on 52)

An expression vector comprising the nucleic acid molecule of claim 52.

### Claim 54 (depends on 53)

A host cell comprising the expression vector of claim 53.

### Claim 55 (depends on 22)

A transgenic mouse comprising immunoglobulin heavy and light chain transgenes, wherein the mouse expresses the antibody or the antigen-binding portion thereof of claim 22.

### Claim 56 (depends on 55)

A hybridoma prepared from the mouse of claim 55, wherein the hybridoma produces said antibody.

### Claim 57 (depends on 22)

A method of modulating an immune response in a subject comprising administering to the subject the antibody, or antigen-binding portion thereof, of claim 22 such that the immune response in the subject is modulated.

### Claim at position 12

58-63. (canceled)

### Claim 64 (depends on 22)

A method of inhibiting growth of tumor cells in a subject, comprising administering to a subject the antibody, or antigen-binding portion thereof, of claim 22 in an amount effective to inhibit growth of the tumor cells.

### Claim 65 (depends on 22)

A method of treating an infectious disease in a subject comprising administering to the subject the antibody, or antigen-binding portion thereof, of claim 22 such that the subject is treated for the infectious disease.

### Claim at position 15

66-68. (canceled)

### Claim 69 (depends on 22)

A method for treating a hyperproliferative disease, which method comprises:
(a) administering an anti-PD-1 antibody to a subject, and
(b) administering an anti-CTLA-4 antibody to the subject,
wherein the anti-PD-1 antibody comprises the antibody of claim 22.

### Claim at position 17

70-104. (canceled)

### Claim 105

A method for preparing an anti-PD-1 antibody comprising:
(a) providing: (i) a heavy chain variable region antibody sequence comprising a CDR1 sequence that is selected from the group consisting of SEQ ID NOs: 15, 16, 17, 18, 19, 20 and 21, a CDR2 sequence that is selected from the group consisting of SEQ ID NOs: 22, 23, 24, 25, 26, 27 and 28; and a CDR3 sequence that is selected from the group consisting of SEQ ID NOs: 29, 30, 31, 32, 33, 34 and 35; or (ii) a light chain variable region antibody sequence comprising a CDR1 sequence that is selected from the group consisting of SEQ ID NOs: 36, 37, 38, 39, 40, 41 and 42, a CDR2 sequence that is selected from the group consisting of SEQ ID NOs: 43, 44, 45, 46, 47, 48 and 49, and a CDR3 sequence that is selected from the group consisting of SEQ ID NOs: 50, 51, 52, 53, 54, 55 and 56;
(b) altering at least one amino acid residue within at least one variable region antibody sequence, said sequence being selected from the heavy chain variable region antibody sequence and the light chain variable region antibody sequence, to create at least one altered antibody sequence; and
(c) expressing the altered antibody sequence as a protein.

### Claim 106 (depends on 22)

The antibody of claim 22, wherein the antibody or antigen-binding portion thereof exhibits at least one of the following properties:
(i) binds to human PD-1 with a KD of 1×10−7 M or less, wherein the KD is measured by surface plasmon resonance (Biacore) analysis;
(ii) binds to human PD-1 with an on rate (kon) of about 0.76×105 l/Ms or more, wherein the on rate (kon) is measured by surface plasmon resonance (Biacore) analysis; and
(iii) binds to human PD-1 with an off rate (koff) of about 4.5×10−4 l/s or less, wherein the off rate (koff) is measured by surface plasmon resonance (Biacore) analysis.

### Claim 107 (depends on 22)

The antibody of claim 22, wherein:
(a) the heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 15; the heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 22; the heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 29; the light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 36; the light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 43; and the light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 50;
(b) the heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 16; the heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 23; the heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 30; the light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 37; the light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 44; and the light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 51;
(c) the heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 17; the heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 24; the heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 31; the light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 38; the light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 45; and the light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 52;
(d) the heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 18; the heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 25; the heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 32; the light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 39; the light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 46; and the light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 53;
(e) the heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 19; the heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 26; the heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 33; the light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 40; the light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 47; and the light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 54;
(f) the heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 20; the heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 27; the heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 34; the light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 41; the light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 48; and the light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 55; or
(g) the heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 21; the heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 28; the heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 35 the light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 42; the light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 49; and the light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 56.

### Claim 108 (depends on 22)

The antibody of claim 22, wherein:
(a) the heavy chain variable region comprises amino acids having the sequence set forth in SEQ ID NO: 1; and the light chain variable region comprises amino acids having the sequence set forth in SEQ ID NO: 8;
(b) the heavy chain variable region comprises amino acids having the sequence set forth in SEQ ID NO: 2; and the light chain variable region comprises amino acids having the sequence set forth in SEQ ID NO: 9;
(c) the heavy chain variable region comprises amino acids having the sequence set forth in SEQ ID NO: 3; and the light chain variable region comprises amino acids having the sequence set forth in SEQ ID NO: 10;
(d) the heavy chain variable region comprises amino acids having the sequence set forth in SEQ ID NO: 4; and the light chain variable region comprises amino acids having the sequence set forth in SEQ ID NO: 11;
(e) the heavy chain variable region comprises amino acids having the sequence set forth in SEQ ID NO: 5; and the light chain variable region comprises amino acids having the sequence set forth in SEQ DD NO: 12;
(f) the heavy chain variable region comprises amino acids having the sequence set forth in SEQ ID NO: 6; and the light chain variable region comprises amino acids having the sequence set forth in SEQ ID NO: 13; or
(g) the heavy chain variable region comprises amino acids having the sequence set forth in SEQ ID NO: 7; and the light chain variable region comprises amino acids having the sequence set forth in SEQ ID NO: 14.

### Claim 109 (depends on 22)

The antibody of claim 22, wherein the antibody or antigen-binding portion thereof is a humanized or human monoclonal antibody or an antigen-binding portion thereof.

### Claim 110 (depends on 22)

The antibody of claim 22, wherein the antibody further comprises a heavy chain constant region which is of a human IgG4.

### Claim 111 (depends on 22)

The antibody of claim 22, wherein the antibody or antigen-binding portion thereof comprises a light chain constant region which is a human kappa or lambda constant region.

### Claim 112 (depends on 22)

The antibody of claim 22, wherein the antigen-binding portion is a Fab, Fab′, F(ab′)2, Fv, or a single chain Fv fragment.
